Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Hematologic, Immune, or Bone Marrow Disorders: early-phase trial registry

1 of 1 indexed Hematologic, Immune, or Bone Marrow Disorders trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Hematologic, Immune, or Bone Marrow Disorders: 1 US clinical trial tracked, 1 recruiting.

Hematologic, Immune, or Bone Marrow Disorders is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 1 of these trials.

Enrollment posture brief

Registry condition hematologic-immune-or-bone-marrow-disorders

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Hematologic, Immune, or (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hematologic, Immune, or Bone Marrow Disorders

Hematologic, Immune, or Bone Marrow Disorders lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hematologic, Immune, or Bone Marrow Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hematologic, Immune, or Bone Marrow Disorders is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Hematologic, Immune, or Bone Marrow Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

GVHD Regimen B: BM Recipients Drug
1 trials
GVHD Regimen A: UCB Recipients Drug
1 trials
Treatment Plan 2: Strata 2, 3, or 4 Drug
1 trials
Treatment Plan 1: Stratum 1 Drug
1 trials

US sites by state

Facility locations filed on Hematologic, Immune, or Bone Marrow Disorders trials. A trial with sites in several states counts in each.

New York 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials
Louisiana 1 trials
Indiana 1 trials
Illinois 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hematologic, Immune, or Bone Marrow Disorders page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic, Immune, or Bone Marrow Disorders condition card totals 1 registered trials; most-linked intervention GVHD Regimen B: BM Recipients; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.